Connect with Us at the Upcoming Events

With in-person events back again, Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at 2022 BIO International Convention in June (booth #1754) and at the 13th Annual World ADC San Diego in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!

Book a Meeting


CellFace™ NK Cell-Antibody Cixutumumab Biosimilar (Anti-IGF1 Receptor) Conjugate (CAT#: CF-AB-P839)

Product Overview
DescriptionEmploying live cells as therapeutics is a direction of future drug discovery. An easy and robust method to modify the surfaces of cells directly to incorporate novel functionalities is highly desirable. However, genetic methods for cell-surface engineering are laborious and limited by low efficiency for primary cell modification. Creative Biolabs has developed a single-step chemoenzymatic CellFace™ technology platform to transfer bio-macromolecules, such as an IgG antibody (MW∼ 399 KD), to the glycocalyx on the surfaces of live cells. Requiring no genetic modification, our CellFace™ allows for any antibody to be conjugated to the stimulatory surface receptors of immune cells to yield the additive effect of superior tumor targeting to its already potent and off-the-shelf biologic drug payloads.

We applied CellFace™ method to construct the CellFace™ T cell-antibody conjugate. The CellFace™ NK Cell-Antibody Cixutumumab (Anti-IGF1 Receptor) Conjugate is constructed from a NK cell line modified with anti-IGF1 Receptor Cixutumumab antibody. The modified NK cell-conjugate is expected to exhibit novel functions of specific tumor targeting in Cancers and can be used as a research tool for therapeutic applications.
CellFace™ PlatformCreative Biolabs' CellFace™ Conjugate Technology is a single-step, chemical enzyme-based approach that can quickly engineer cell surfaces in minutes. Through this fast, simple and cost-effective technique, biomacromolecules including proteins (antibodies, antigens) and nucleic acids, as well as small molecule probes such as fluorescent and biophysical probes, are efficiently conjugated without the need for genetic modification of host cells.

A unique catalytic enzyme that transfers the conjugate to the cell surface of living cells in a matter of minutes

A single-step chemical enzymatic reaction method provides a general method for engineering cells as a research tool and for therapeutic applications

A one-pot approach to combine the synthesis of GDP-fucose derivatives with the subsequent transfer and made this engineering technology practical and cost-effective
Cell TypeNK Cell
ApplicationsCell Therapy
Application NotesThe antibody-cell conjugates (ACCs) can be customized with both cell lines and primary cells according to customer needs.
Relevant DiseasesCancers
CloneCixutumumab [Research Grade Biosimilar]
Clone AliasA12; IMC-A12; LY3012217; NSC 742460
TypeWhole Antibody
IsotypeHuman Therapeutic Antibody
TargetIGF1 Receptor
Official NameIGF1R
Full NameInsulin Like Growth Factor 1 Receptor
SynonymsCixutumumab;947687-12-9;IMC-A12;NSC742460;IGF1R;insulin-like growth factor 1 receptor;CD221;IGFIR;IGFR;JTK13;MGC18216;IGF-I receptor;soluble IGF1R variant 1;soluble IGF1R variant 2;insulin-like growth factor I receptor;MGC142170;MGC142172;
Gene ID3480
Uniprot IDP08069
Quality Control
Cell Purity>95%
Cell Viability>90%
Mycoplasma TestingThe cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
Sterility TestingCreative Biolabs provides sterility testing in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
Research Use OnlyFor research use only, not for diagnostic or therapeutic use.

Related products

All services are only provided for research purposes and Not for clinical use.


  • *
  • *
  • *

United Kingdom